Bespak is increasing pressurized metered dose inhaler manufacturing capacity to support Chiesi Group’s Carbon Minimal Inhaler (CMI) program.

Kenox Pharmaceuticals Inc. (Kenox), a fast‑growing contract development and manufacturing organization (CDMO) dedicated exclusively to Orally Inhaled and Nasal Drug Products (OINDPs) and Ophthalmic ...

Kindeva, a CDMO focused on drug delivery devices, hauled in a 33 million pound sterling ($42.1 million) grant from the U.K.’s Life Sciences Innovation Manufacturing Fund that will be used to bolster ...

Agreement builds on existing Chiesi-Bespak collaboration, reinforcing a trusted relationship as Chiesi works to evolve a portfolio of extrafine formulation Carbon Minimal Inhalers 1, ensuring patients ...

A shuttered Milanese manufacturing site with a storied history is getting a new lease on life, thanks to a nearly half-a-billion-dollar investment from Italian drugmaker Chiesi. As part of an ongoing ...

Over the last two years, big pharma has gotten behind the idea of smartphone-connected inhalers for asthma and COPD in a big way. Two acquisitions, a $3 million investment, and a number of pilot and ...

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Pharma, a global leader in drug delivery and active material science solutions and services, today announced that it has entered into an exclusive ...

Two Minneapolis-based companies – digital health care management program maker HealthFactors and medical-focused R&D firm Koronis BioMedical Technologies (KBT) – are working together to create new ...

What is Pharma 4.0? The term Industry 4.0 refers to the fourth industrial revolution, associated with the application of advanced technologies that have dramatically changed the landscape of ...